ANALYSIS OF SAFETY OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER (RESULTS OF A MULTICENTER RANDOMIZED TRIAL)

The purpose of the study was to immediate results of neoadjuvant chemoradiotherapy in patients with locally advanced gastric cancer were analyzed in a multicenter randomized trial.
Material and Methods. The comparative analysis of neoadjuvant chemotherapy regimens, toxicity and postoperative complications was carried out. Patients of the study group received conformal radiation therapy (46 Gy in 2 Gy daily fractions) concurrently with chemotherapy with Capecitabine at a dose of 1850 mg/m² divided in two equal doses during the course of radiation therapy, and Oxaliplatin at a dose of 85 mg/m² on days 1 and 21. After an interval of 4–6 weeks and a control examination, in the absence of evident disease progression, patients were scheduled for surgery (gastrectomy or subtotal gastrectomy with D2 lymph node dissection) and 4 cycles of adjuvant chemotherapy according to the FOLFOX4 or CAPOX regimen. The treatment program for patients in the control group included surgery (gastrectomy or subtotal gastrectomy with D2 lymph node dissection) after randomization, and 6 cycles of adjuvant chemotherapy using the same regimens. The study included 70 patients with an equal distribution between groups.
Results. Among the patients of the study group, grade 1 and 2 toxicity was the most common; grade 3 toxicity occurred in 9 cases; grade 4 and 5 toxicity was not observed. Among the manifestations of hematological toxicity, thrombocytopenia and leukopenia were the most common (57–60 % of patients), and grade 3 hematological toxicity was observed in 6 (17.1 %) cases. Among the manifestations of gastrointestinal toxicity, nausea, vomiting and decreased appetite prevailed; grade 3 toxicity was observed only in 3 (8.6 %) cases. The radiation component of neoadjuvant therapy was completed in 32 (91 %) patients. Both protocol-prescribed oxaliplatin infusions were performed in 34 (97 %) patients. Changes in capecitabine administration were required in 8 patients. Immediately before surgery, some patients had grade 1–2 toxicity, which did not prevent performing surgery. There were no statistically significant differences in the frequency and severity of complications in the early postoperative period between the comparison groups. Grade 1–2 postoperative complications were the most common.

gastric cancer, neoadjuvant chemoradiotherapy, combination treatment, multicenter randomized trial, toxicity, postoperative complications

1. Rawla P., Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019; 14(1): 26–38. doi: 10.5114/pg.2018.80001.

2. Kaprin A.D., Starinsky V.V., Petrova G.V. The status of cancer care for the population of Russia in 2017. Moscow, 2018. 250 p. (in Russian).

3. Amin M.B., Greene F.L., Edge S.B., Compton C.C., Gershenwald J.E., Brookland R.K., Winchester D.P. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. Cancer J Clin. 2017; 67(2): 93–99.

4. Klevebro F., Nilsson M. The role of neoadjuvant chemoradiotherapy in multimodality treatment of esophageal or gastroesophageal junction cancer. J Thorac Dis. 2018 Jan; 10(1): E87E89. doi: 10.21037/jtd.2017.11.139.

5. Beeharry M.K., Zhang T.Q., Liu W.T., Gang Z.Z. Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J Surg Oncol. 2020 Mar 9; 18(1): 51. doi: 10.1186/s12957-020-01819-6.

6. Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.G., Mayer F., Haag G.M., Luley K., Lindig U., Schmiegel W., Pohl M., Stoehlmacher J., Folprecht G., Probst S., Prasnikar N., Fischbach W., Mahlberg R., Trojan J., Koenigsmann M., Martens U.M., Thuss-Patience P., Egger M., Block A., Heinemann V., Illerhaus G., Moehler M., Schenk M., Kullmann F., Behringer D.M., Heike M., Pink D., Teschendorf C., Löhr C., Bernhard H., Schuch G., Rethwisch V., von Weikersthal L.F., Hartmann J.T., Kneba M., Daum S., Schulmann K., Weniger J., Belle S., Gaiser T., Oduncu F.S., Güntner M., Hozaeel W., Reichart A., Jäger E., Kraus T., Mönig S., Bechstein W.O., Schuler M., Schmalenberg H., Hofheinz R.D.; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019 May 11; 393(10184): 1948–1957. doi: 10.1016/S0140-6736(18)32557-1.

7. Schulz C., Kullmann F., Kunzmann V., Fuchs M., Geissler M., Vehling-Kaiser U., Stauder H., Wein A., Al-Batran S.E., Kubin T., Schäfer C., Stintzing S., Giessen C., Modest D.P., Ridwelski K., Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma - Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015 Aug 1; 137(3): 678–85. doi: 10.1002/ijc.29403.

8. Leong T., Smithers B.M., Haustermans K., Michael M., Gebski V., Miller D., Zalcberg J., Boussioutas A., Findlay M., O'Connell R.L., Verghis J., Willis D., Kron T., Crain M., Murray W.K., Lordick F., Swallow C., Darling G., Simes J., Wong R. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017; 24(8): 2252–58. doi: 10.1245/s10434-017-5830-6.

9. Stahl M., Walz M.K., Stuschke M., Lehmann N., Meyer H.J., Riera-Knorrenschild J., Langer P., Engenhart-Cabillic R., Bitzer M., Königsrainer A., Budach W., Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009 Feb 20; 27(6): 851–6. doi: 10.1200/JCO.2008.17.0506.

10. Skoropad V.Y., Afanasyev S.G., Gamayunov S.V., Agababyan T.A., Volkov M.Y., Glushchenko S.A., Evdokimov L.V., Korchagina K.S., Mozerov S.A., Mikhaylova O.A., Popova N.O., Rukhadze G.O., Samtsov E.N., Safonova M.A., Sveklova A.A., Startseva Z.A., Titova L.N., Yakushina Z.K. Planning phase 2 multicenter randomized trial of neoadjuvant chemo-radiotherapy followed by d2 gastrectomy and adjuvant chemotherapy for locally advanced gastric cancer. Siberian Journal of Oncology. 2016; 15(2): 12–20. (in Russian). doi: 10.21294/1814-4861-2016-15-2-12-20.

11. Skoropad V.Yu., Afanasyev S.G., Gamayunov S.V., Silantyev N.K., Agababyan T.A., Sokolov P.V., Ivanov S.A., Kaprin A.D. Phase 2 multicenter randomized clinical trial: neoadjuvant chemoradiotherapy followed by D2 gastrectomy and adjuvant chemotherapy in patients with locally advanced gastric cancer. Siberian Journal of Oncology. 2020; 19(1): 5–14. (in Russian). doi: 10.21294/1814-4861-2020-19-1-5-14.

12. Chakravarty T., Crane C.H., Ajani J.A., Mansfield P.F., Briere T.M., Beddar A.S., Mok H., Reed V.K., Krishnan S., Delclos M.E., Das P. Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 1; 83(2): 581–6. doi: 10.1016/j.ijrobp.2011.07.035.

13. Lee D.J., Sohn T.S., Lim D.H., Ahn H.K., Park S.H., Lee J., Park J.O., Park Y.S., Lim H.Y., Choi D.I., Kim K.M., Choi M.G., Noh J.H., Bae J.M., Kim S., Min B.H., Kang W.K. Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol. 2012 May; 69(5): 1333–8. doi: 10.1007/s00280-012-1836-8.

14. Trip A.K., Poppema B.J., van Berge Henegouwen M.I., Siemerink E., Beukema J.C., Verheij M., Plukker J.T., Richel D.J., Hulshof M.C., van Sandick J.W., Cats A., Jansen E.P., Hospers G.A. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiother Oncol. 2014 Aug; 112(2): 284–8. doi: 10.1016/j.radonc.2014.05.003.

15. Wydmański J., Suwinski R., Poltorak S., Maka B., Miszczyk L., Wolny E., Bielaczyc G., Zajusz A. The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study. Radiother Oncol. 2007 Feb; 82(2): 132–6. doi: 10.1016/j.radonc.2007.01.009.